drug_type
RELEVANT_DRUG
intervention_type
Biological: broadly neutralizing monoclonal antibody (bNAb)
drug_description
A recombinant human broadly neutralizing monoclonal antibody that targets the HIV-1 gp120 V3-glycan (N332) supersite to inhibit viral entry; neutralizes diverse HIV-1 strains and can mediate Fc-dependent effector functions (ADCC/ADCP). The LS Fc mutations enhance FcRn binding and extend serum half-life.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Broadly Neutralizing Antibodies
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
10-1074-LS is a broadly neutralizing human monoclonal antibody that binds the HIV-1 Env gp120 V3-glycan (N332) supersite, blocking Env–CD4 interactions and viral attachment/entry to neutralize diverse HIV-1 strains. Its Fc region can engage Fcγ receptors to mediate effector functions such as ADCC and ADCP, aiding clearance of virions/infected cells. LS Fc mutations (M428L/N434S) enhance FcRn binding, extending serum half-life.
drug_name
10-1074-LS
nct_id_drug_ref
NCT05300035